The estimated Net Worth of James Vollins is at least $913 Tysiąc dollars as of 4 February 2022. Mr. Vollins owns over 18,541 units of Biodelivery Sciences International stock worth over $55,184 and over the last 6 years he sold BDSI stock worth over $129,071. In addition, he makes $728,757 as Chief Compliance Officer, General Counsel oraz Corporate Secretary at Biodelivery Sciences International.
Sign up
Mr. Vollins BDSI stock SEC Form 4 insiders trading
James has made over 8 trades of the Biodelivery Sciences International stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 18,541 units of BDSI stock worth $66,748 on 4 February 2022.
The largest trade he's ever made was exercising 29,825 units of Biodelivery Sciences International stock on 14 December 2020 worth over $103,195. On average, James trades about 9,871 units every 54 days since 2018. As of 4 February 2022 he still owns at least 9,872 units of Biodelivery Sciences International stock.
You can see the complete history of Mr. Vollins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
James Vollins biography
James Vollins J.D., is the Chief Compliance Officer, General Counsel, Corporate Secretary of the Company. Mr. Vollins has twenty-five years of legal experience with over ten years of in-house experience in the pharmaceutical industry, which includes work on several major strategic transactions and a successful initial public offering. From 2014 to 2018, Mr. Vollins was General Counsel, Chief Compliance Officer and Corporate Secretary for Bio Products Laboratory Limited, a UK based manufacturer of plasma-derived therapies, where he helped lead the transformation of the business from a government owned not-for-profit to a high-performing commercial enterprise that successfully launched three new drugs in the U.S., expanded its sales force, and achieved significant revenue growth. Mr. Vollins has also worked for other industry-leading pharmaceutical companies, including Grifols Inc., Talecris Biotherapeutics, Inc. and Pfizer Inc.
What is the salary of James Vollins?
As the Chief Compliance Officer, General Counsel oraz Corporate Secretary of Biodelivery Sciences International, the total compensation of James Vollins at Biodelivery Sciences International is $728,757. There are 3 executives at Biodelivery Sciences International getting paid more, with Scott Plesha having the highest compensation of $1,503,860.
How old is James Vollins?
James Vollins is 51, he's been the Chief Compliance Officer, General Counsel oraz Corporate Secretary of Biodelivery Sciences International since 2018. There are 11 older and 3 younger executives at Biodelivery Sciences International. The oldest executive at Biodelivery Sciences International is William Watson, 69, who is the Independent Director.
What's James Vollins's mailing address?
James's mailing address filed with the SEC is C/O EIGER BIOPHARMACEUTICALS, INC., 2155 PARK BLVD., PALO ALTO, CA, 94306.
Insiders trading at Biodelivery Sciences International
Over the last 21 years, insiders at Biodelivery Sciences International have traded over $111,671,776 worth of Biodelivery Sciences International stock and bought 1,813,177 units worth $5,352,510 . The most active insiders traders include International, L.P. Elliott, Associates, L.P. Elliott oraz Healthcare Master Fund Ltd .... On average, Biodelivery Sciences International executives and independent directors trade stock every 18 days with the average trade being worth of $420,648. The most recent stock trade was executed by Jeffrey Allen Bailey on 9 March 2022, trading 5,333 units of BDSI stock currently worth $29,811.
What does Biodelivery Sciences International do?
BioDelivery Sciences International, Inc. is a commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI has built a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI's marketed products address serious and debilitating conditions, including chronic pain and opioid-induced constipation.
What does Biodelivery Sciences International's logo look like?
Complete history of Mr. Vollins stock trades at Biodelivery Sciences International i Eiger BioPharmaceuticals Inc
Biodelivery Sciences International executives and stock owners
Biodelivery Sciences International executives and other stock owners filed with the SEC include:
-
Scott Plesha,
President, Chief Commercial Officer -
Mary Coelho,
Chief Financial Officer, Treasurer -
Thomas Smith,
Chief Medical Officer -
James Vollins,
Chief Compliance Officer, General Counsel, Corporate Secretary -
Scott M. Plesha,
Pres & Chief Commercial Officer -
James Vollins J.D.,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Dr. Thomas B. Smith FAAFP, M.D.,
Chief Medical Officer -
Vanila Singh,
Independent Director -
Mark Sirgo,
Vice Chairman of the Board -
Todd Davis,
Independent Director -
Peter Greenleaf,
Independent Chairman of the Board -
William Watson,
Independent Director -
Kevin Kotler,
Independent Director -
Kevin Ostrander,
Senior Vice President - Business Development -
Joseph Lockhart,
Senior Vice President - Operations -
Jeffrey Bailey,
Chief Executive Officer -
Dr. Jeff Katz,
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board -
Dr. Arthur G. Lipman PharmD,
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board -
Dr. Bill McCarberg,
Member of Scientific Advisory Board and Member of Arius Scientific Advisory Board -
John Golubieski,
CFO & Chief Accounting Officer -
Niraj Vasisht,
Chief Technology Officer -
Samuel P Jr Sears,
Director -
Barry I Feinberg,
Director -
Charles Bramlage,
Director -
William B Stone,
Director -
Francis E Jr Odonnell,
Director -
Thomas D'alonzo,
Director -
Healthcare Master Fund Ltd ...,
-
Timothy Tyson,
Director -
W. Mark Watson,
Director -
Kevin Broadfin Healthcare M...,
-
Herm Cukier,
Chief Executive Officer -
John J Shea,
Director -
Iv Llc Ramsay David Russ Le...,
-
Capital Group Ii Llc Hopkins,
10% owner -
Allan Pearce,
Director -
James R Butler,
Director -
Paolantonio Ernest Robert De,
CFO and Secretary -
Associates, L.P. Elliott,
10% owner -
James A Mcnulty,
Chief Financial Officer -
William Poole,
Director -
Kathleen M Tr Irrev Tr 1 Fb...,
10% owner -
Raphael J Mannino,
Executive Vice President & CSO -
Donald Ferguson,
Director -
Iv Llccdc Operations Llc Ra...,
-
International, L.P. Elliott,
10% owner -
L M Stephenson,
Director -
Capital Group Llc Hopkins,
10% owner -
Kathleen M O Donnell,
10% owner -
Benny Ward,
EVP of Busi. & Strategic Dev. -
John Golubieski,
See Remarks